Michael Galitz, MD
Endocrinology, Diabetes & Metabolism · Mobile, ALNPI 1275503690
Payments from drug & device makers
Across 524 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- Novo Nordisk$1K
- Dexcom, Inc.$830
- Bayer$643
- Amgen$495
- Xeris Pharmaceuticals, Inc.$491
- plus $4K from 31 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 90 | $1,667 |
| Novo Nordisk | 89 | $1,151 |
| Dexcom, Inc. | 67 | $830 |
| Bayer | 33 | $643 |
| Amgen(2 entities) | 17 | $495 |
| Xeris Pharmaceuticals, Inc. | 20 | $491 |
| Sanofi-aventis U.S. LLC | 23 | $436 |
| Boehringer Ingelheim | 23 | $430 |
| BETA Bionics, Inc. | 11 | $402 |
| Antares Pharma, Inc. | 14 | $387 |
| Corcept Therapeutics | 19 | $348 |
| Abbott | 14 | $267 |
| Novartis | 18 | $228 |
| AbbVie | 10 | $214 |
| AstraZeneca(2 entities) | 11 | $196 |
| Amarin Pharma, Inc. | 8 | $152 |
| Tandem Diabetes Care, Inc. | 8 | $148 |
| Insulet Corporation | 7 | $140 |
| Medtronic | 3 | $110 |
| Rhythm Pharmaceuticals, Inc. | 5 | $108 |
| IBSA Pharma Inc. | 5 | $95 |
| Amryt Pharma Holdings Ltd | 4 | $85 |
| Radius Health, Inc. | 3 | $74 |
| Recordati_rare_diseases_inc. | 3 | $61 |
| Chiesi USA, Inc. | 2 | $47 |
| Amneal Pharmaceuticals LLC | 2 | $41 |
| Sequel Med Tech, LLC | 2 | $39 |
| Kyowa Kirin, Inc. | 2 | $38 |
| Mannkind Corporation | 2 | $36 |
| Pfizer | 2 | $30 |
| GSK | 1 | $23 |
| EUSA Pharma (US) LLC | 1 | $20 |
| Halozyme Inc | 1 | $19 |
| Ascendis Pharma Endocrinology Inc | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Averitas Pharma Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
How this compares
$9,515 in reported general payments places this provider in the 55th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Mobile
- Wilburn BoltonMobile$52K
- Anita KemmerlyMobile$13K
- Michael DavisMobile$12K
- Heather FishelMobile$11K
- Jocelyn HewittMobile$9K
- Huey McDanielMobile$8K
- Stephen DavisMobile$7K
- Ross del FierroMobile$6K
- Jessica BhathalMobile$6K
- William GarveyBirmingham$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.